Background Drug-eluting stents (DES) have been shown to significantly reduce clinical events and angiographic restenosis in the treatment of coronary artery disease (CAD). We aimed to assess the long-term efficacy and safety of two Sirolimus-Eluting Stents (the biodegradable polymer-coated sirolimus-eluting stents, EXCEL and the polymer-based sirolimus-eluting cobalt-chromium stents, Firebird 2) in the treatment of patients with CAD and Type 2 Diabetes.
Methods A total of 320 consecutive patients with coronary artery disease and type 2 diabetes undergoing percutaneous coronary intervention randomised into two groups (EXCEL group, n=158; Firebird 2 group, n=162). Baseline clinical characteristics, procedural success rate and occurrence of major adverse cardiac events (MACE, a composite of death, myocardial infarction or target lesion revascularisation) during follow-up were recorded and compared between the two groups.
Results During hospitalisation no patient had complications. At 1 year follow-up, both of the EXCEL group and Firebird 2 group had lower occurrence of cardiac events (1.9% in the Excel group and 1.2% in the Firebird group, p>0.05).
Conclusion Implantation of EXCEL stent or Firebird 2 stent for patients with coronary artery disease and type 2 diabetes is safe and can reduce major adverse cardiac events in long-term follow-up.